Literature DB >> 1665119

The randomized concentration-controlled trial: an evaluation of its sample size efficiency.

L P Sanathanan1, C C Peck.   

Abstract

A randomized concentration-controlled trial (RCCT) is one in which subjects are randomly assigned to predetermined levels of average plasma drug concentration. These target concentrations can be achieved (within reasonable ranges) by an individualized pharmacokinetically controlled dosing scheme. The RCCT is designed to minimize the interindividual pharmacokinetic (PK) variability within comparison groups and consequently decrease the variability in clinical response within these groups. In this paper, we investigate the extent of improvement in sample size efficiency that can be gained from the RCCT design in comparison to the traditional randomized dose-controlled trial (RDCT) design. Our investigations involve both theoretical arguments and simulation studies, illustrated with data on PK and pharmacodynamic (PD) characteristics of the antiasthma drug theophylline. Aside from safety concerns that strongly suggest the use of RCCT for drugs with narrow therapeutic windows, sample size considerations favor the choice of RCCT in many situations, as shown in this paper.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1665119     DOI: 10.1016/0197-2456(91)90041-j

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  25 in total

1.  Target concentration intervention: beyond Y2K.

Authors:  N H Holford
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 2.  Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials?

Authors:  A Grahnén; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 4.  Quantitative clinical pharmacology is transforming drug regulation.

Authors:  Carl C Peck
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-10-27       Impact factor: 2.745

Review 5.  On some "disadvantages" of the population approach.

Authors:  Jerry R Nedelman
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

6.  Randomized exposure-controlled trials; impact of randomization and analysis strategies.

Authors:  Kristin E Karlsson; Anders Grahnén; Mats O Karlsson; E Niclas Jonsson
Journal:  Br J Clin Pharmacol       Date:  2007-04-10       Impact factor: 4.335

Review 7.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 8.  The use of population pharmacokinetics in drug development.

Authors:  S Vozeh; J L Steimer; M Rowland; P Morselli; F Mentre; L P Balant; L Aarons
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

9.  Imipramine and mirtazapine are less effective than expected.

Authors:  R M Pinder; M Zivkov
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

Review 10.  Is there a role for therapeutic drug monitoring of new anticonvulsants?

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.